Showing results (21-30 of 38) with videos related to

Sort By:
Pageof 4
Biorxiv : the Preprint Server for Biology|November 24, 2025
A Rapid Gene Expression Profiler Classifies AML Tumor Responsiveness to Standard TherapiesStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.
Blood|November 15, 2018
CSF1R inhibitors exhibit antitumor activity in acute myeloid leukemia by blocking paracrine signals from support cellsDavid K Edwards, Kevin Watanabe-Smith, Angela Rofelty, et al.
Leukemia|May 11, 2018
Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypesMona M Hosseini, Stephen E Kurtz, Sherif Abdelhamed, et al.
Cell Reports. Medicine|December 30, 2025
CDK4/6 inhibition overcomes venetoclax resistance mechanisms with enhanced combination activity in acute myeloid leukemiaMelissa L Stewart, Jessica Gibbs, Kevin Watanabe-Smith, et al.
Scientific Reports|January 17, 2018
Modulation of UVB-induced Carcinogenesis by Activation of Alternative DNA Repair PathwaysYan Sha, Vladimir Vartanian, Nichole Owen, et al.
Frontiers in Immunology|December 25, 2025
The aryl hydrocarbon receptor is associated with monocytic AML and innate immune resistance reversible with an AHR inhibitorJennifer N Saultz, Daniel Bottomly, Faith Burns, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity ModelMax J Gordon, Andy Kaempf, Andrea Sitlinger, et al.
Blood Cancer Discovery|September 12, 2023
Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia TherapyChristopher A Eide, Stephen E Kurtz, Andy Kaempf, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 9, 2017
Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignanciesStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.
Blood Advances|February 3, 2023
A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphomaGeoffrey Shouse, Andy Kaempf, Max J Gordon, et al.
Pageof 4